Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2221 to 2235 of 7682 results

  1. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    In development [GID-TA11394] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. O2Matic pro 100 (MT746)

      Status ...

    Medical technologies guidance
    Topic selection

  3. Signatera molecular residual disease assay (MT741)

      Status ...

    Medical technologies guidance
    Topic selection

  4. Stockholm3 blood test for prostate cancer, (MT734),

      Status ...

    Diagnostics guidance
    Topic selection

  5. PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes, (MT740)

      Status ...

    Diagnostics guidance
    Topic selection

  6. Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy, (MT158)

      Status ...

    Diagnostics guidance
    Topic selection

  7. Jada, (MT826)

      Status ...

    Medical technologies guidance
    Topic selection

  8. Urolon, (MT821)

      Status ...

    Medical technologies guidance
    Topic selection

  9. BPMpathway for rehabilitation support in joint replacement surgery, (MIB319)

      Status ...

    Medical technologies guidance
    Topic selection

  10. LIVERFASt for diagnosing and staging liver injury and chronic liver disease, (MT783)

      Status ...

    Diagnostics guidance
    Topic selection

  11. iQoro neuromuscular training device, (MT809)

      Status ...

    Medical technologies guidance
    Topic selection

  12. Spectra Optia for plasma exchange, (MT828)

      Status ...

    Medical technologies guidance
    Topic selection

  13. Electrosurgery (diathermy and coblation) for tonsillectomy, (IP324/2)

      Status ...

    Medical technologies guidance
    Topic selection

  14. Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations TSID 12011

      Status ...

    Technology appraisal guidance
    Topic selection

  15. Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021

    Awaiting development [GID-TA11556] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development